Enthea
United States
- Boston
- 19/12/2022
- Seed
- $2,000,000
Psychedelic Healthcare as a Workplace Benefit.
Creating benefit plans for progressive, compassionate employers.
We are on a mission to expedite safe, affordable access to psychedelic-assisted therapy for all who can benefit.
Supporting healing from within.
- Industry Insurance and Employee Benefit Funds
- Website https://www.enthea.com/
- LinkedIn https://www.linkedin.com/company/entheahealth/
Related People
Sherry R.Founder
Canada -
Toronto, Ontario
I have helped dozens of startups, non-profit organizations, academic/research institutions, and small businesses raise funds, operate according to their mission and values, and implement processes that enhance their efficiency.
I believe in living and working in alignment with purpose and I am currently focused on expanding access to psychedelic-assisted therapy to alleviate human suffering.
Before this, I consulted with the United Nations and World Bank for 10 years, implementing cash transfer programs at the national level in over 35 countries.
I have a Master’s Degree in Public Policy and Management from the London School of Economics and a Bachelor’s Degree in Neuroscience and International Development from McGill University. I also completed the Certificate in Psychedelic Therapies and Research from CIIS in 2021.
In addition to being Enthea's CEO, I am the Executive Director of the Boston Psychedelic Research Group, HR Consultant for Sensorium Therapeutics, and Strategic Advisor for CIIS.
Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)